Healthcare Professionals Advised That Aqueous Cream May Cause Skin Irritation, Particularly in Children with Eczema
The Medicines and Healthcare products Regulatory Agency (MHRA) has advised healthcare professionals that aqueous cream may cause local skin reactions, such as stinging, burning, itching and redness when used as a leave-on moisturiser, particularly in children with eczema. The reactions, which are not generally serious, often occur within 20 minutes of application but can occur later. Reactions may be due to the presence of sodium lauryl sulfate or other ingredients. If skin irritation occurs with the use of aqueous cream, treatment should be discontinued and an alternative moisturising cream that does not contain sodium lauryl sulfate should be tried. Aqueous cream is widely used to relieve dry skin conditions such as eczema, and as a soap substitute for skin washing. For more information please visit: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON254804
Learn More

Healthcare Professionals Advised to Reduced Steroid Doses Cautiously in Patients Taking Nulojix
Bristol-Myers Squibb Pharmaceuticals has written to healthcare professionals to advise them that doses of corticosteroid treatment should be reduced carefully in patients prescribed Nulojix (belatacept). This advice follows reports of organ rejection following kidney transplant, where doses of corticosteroids have been rapidly reduced in patients taking Nulojix. Nulojix contains the medicine belatacept and is used to suppress the immune system in patients who have received a kidney transplant in order to reduce the risk that the body will reject the transplant. Corticosteroids are used to suppress inflammation and include drugs such as prednisolone, methylprednisolone, hydrocortisone, dexamethasone, triamcinolone, deflazacort, beclometasone, and budesonide. For more information please visit: http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con260277.pdf
Learn More